Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 27 November 2017, 11:38 HKT/SGT
Share:
    

Source: Sisram Medical Ltd
Sisram Medical Ltd Increase in Shareholding by Controlling Shareholder and CEO As a Vote of Confidence and Trust in the Company's Future Success

HONG KONG, Nov 27, 2017 - (ACN Newswire) - Sisram Medical Ltd ("Sisram" or the "Company"; stock code: 1696.HK), an investment holding company specializing in medical technology for healthcare ranked #1 in the PRC and one of the top 5 global leaders in the industry, announced the increase in shareholding by the Company's controlling shareholder and CEO.

Ample Up Limited ("Ample Up"), controlling shareholder of Sisram, and Mr. Lior Moshe Dayan, Chief Executive Officer and Executive Director of Sisram, has acquired additional shares of the Company. According to latest announcements, Ample Up has made on-market purchase on The Stock Exchange of Hong Kong Limited ("SEHK") of an aggregate of 288,800 and 270,000 shares of the Company on 21 and 22 November 2017 respectively. Mr. Dayan has made on-market purchases on SEHK of an aggregate of 36,000 shares of the Company. After the increase in shareholding, Ample Up directly and indirectly controls approximately 52.83% and Mr. Dayan controls approximately 0.008% of the total issued shares of the Company.

In the first half of 2017, the Company's revenue was reported US$66.3 million, representing a year over year growth of 12.9%. The Company's adjusted net profit increased by 30.6% to US$13.3 million. The profitability and operational quality of the Company improved continuously. Sisram invest a lot of efforts in promoting its various brands, increasing market awareness and sales of its products, as well as expanding sales and distribution channels. The increase of shareholdings by the company's controlling shareholder and management expresses a vote of confidence in the company and its future roadmap.

Looking forward, Mr. Lior Moshe Dayan said, "Sisram is the first Israeli company listed on the main board of the Hong Kong Stock Exchange, with comprehensive in-house capabilities to design, develop and produce energy-based medical aesthetic treatment systems. In the past 3 years, more than 90% of our revenue was driven from products that we have developed in-house. Moving forward we are committed to significant investments in Research & Development that will produce innovative high-end products to meet the growing opportunities that the global market of energy-based medical aesthetic treatment solutions presents."

About Sisram Medical Ltd
Sisram Medical Ltd. (1696.HK), the first Israeli company listed on the Hong Kong Stock Exchange Main Board, is an investment holding company specializing in medical technology for healthcare. Among its holdings is Alma Lasers, a leading provider of energy-based surgical and medical aesthetic solutions, rating #1 in the Peoples Republic of China and one of the top 5 global leaders in its industry. Sisram Medical is a subsidiary of Fosun Pharma, a leading health & medical industry group in China.

Sisram Medical - Enhancing Quality of Life.
www.sisram-medical.com



Nov 27, 2017 11:38 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Sisram Medical Ltd
Dec 6, 2017 16:34 HKT/SGT
The New ALMA BEAUTY SPADEEP Platform Launched Globally After Receiving Outstanding Feedbacks in the Japanese Market
Sept 29, 2017 18:31 HKT/SGT
Sisram Med Revenue in First Half 2017 Increased 12.9% to US$66.3 Million
Sept 20, 2017 12:57 HKT/SGT
Net Proceeds of approximately HK$877.2 Million from Global Offering; Sisram Med Trading Debut on SEHK on 19 September 2017
Sept 20, 2017 12:34 HKT/SGT
Sisram Med Successfully Listed on Main Board of SEHK
Sept 5, 2017 17:00 HKT/SGT
Sisram Medical Offers price between HK$8.88 and HK$12.35 per share
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: